Delayed Transition to 20-Valent Pneumococcal Conjugate Vaccine in Pediatric National Immunization Programs: Forgone Public Health and Economic Benefit
Delays in implementing PCV20 into pediatric NIPs were projected to have substantial negative public health and economic consequences. These results underscore the necessity for national immunization technical advisory groups, policymakers, health organizations, and manufacturers to accelerate replacement of lower-valent standard-of-care PCVs with PCV20.
Authors
- Johnna Perdrizet (ORCID: https://orcid.org/0000-0002-4260-7607)
- Kyla Hayford (ORCID: https://orcid.org/0000-0002-9872-2313)
- Ayman Sabra (ORCID: https://orcid.org/0000-0001-7971-4652)
- An Ta (ORCID: https://orcid.org/0000-0003-0929-6365)
- Liping Huang (ORCID: https://orcid.org/0000-0003-1623-3397)
- Warisa Wannaadisai
- Aleksandar Ilic
Institutions
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- Pfizer (France) (FR)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Pfizer (Canada) (CA)
- Cytel (United States) (US)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2025-02-03
- DOI
- https://doi.org/10.1007/s40121-025-01108-3
- Citations
- 5
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 6.77
Funders
- Pfizer